Skip to main content
Erschienen in: Neurological Sciences 9/2019

02.05.2019 | Review Article

Neuropsychological disorders in non-central nervous system cancer: a review of objective cognitive impairment, depression, and related rehabilitation options

verfasst von: Fulvia Di Iulio, Luca Cravello, Jacob Shofany, Stefano Paolucci, Carlo Caltagirone, Giovanni Morone

Erschienen in: Neurological Sciences | Ausgabe 9/2019

Einloggen, um Zugang zu erhalten

Abstract

Aim

The objective of the present review was to systematically characterize the types of cognitive impairment that are found in different non-brain types of cancer as measured by objective and validated tests, and also to further examine depression and cognitive function in cancer patients and explore their available rehabilitation treatments.

Results

A total of 29 articles were reviewed. Most of these studies suggest that chemotherapy as well as the combination of chemotherapy and hormonal therapy can influence cognition in different types of cancer patients. Breast cancer patients appear to be the most affected in neuropsychological function, specifically in terms of cognitive impairment and reduced quality of life, as compared to other non-brain solid tumours. Overall, the most impaired functions were verbal ability, memory, executive function, and motor speed.

Conclusion

Chemotherapy-related cognitive dysfunction remains under-recognized and undertreated. The various studies reported differing and non-homogenous findings with mixed results, obtained by self-reporting and web-assisted assessment, with other confounding factors such as age and depression during both cancer diagnosis and treatment. An objective neuropsychological assessment is fundamental to avoid underestimation of the extent of chemobrain. Self-reported and web-assisted assessment may ultimately result in confusion between the neuropsychological signs of chemobrain versus those of depression.
Literatur
1.
Zurück zum Zitat WHO (2018) The International Agency for Research on Cancer (IARC) is part of the World Health Organization (WHO). Latest global cancer data: Cancer burden rises to 18.1 million new cases and 9.6 million cancer deaths in 2018. https://www.who.int/cancer/en/. Accessed 2 Nov 2018 WHO (2018) The International Agency for Research on Cancer (IARC) is part of the World Health Organization (WHO). Latest global cancer data: Cancer burden rises to 18.1 million new cases and 9.6 million cancer deaths in 2018. https://​www.​who.​int/​cancer/​en/​. Accessed 2 Nov 2018
2.
Zurück zum Zitat Akechi T, Okuyama T, Sugawara Y, Nakano T, Shima Y, Uchitomi Y (2004) Major depression, adjustment disorders, and post-traumatic stress disorder in terminally ill cancer patients: associated and predictive factors. J Clin Oncol 22:1957–1965CrossRefPubMed Akechi T, Okuyama T, Sugawara Y, Nakano T, Shima Y, Uchitomi Y (2004) Major depression, adjustment disorders, and post-traumatic stress disorder in terminally ill cancer patients: associated and predictive factors. J Clin Oncol 22:1957–1965CrossRefPubMed
3.
Zurück zum Zitat Breitbart W, Rosenfeld B, Pessin H et al (2000) Depression, hopelessness, and desire for hastened death in terminally ill patients with cancer. JAMA. 284:2907–2911CrossRefPubMed Breitbart W, Rosenfeld B, Pessin H et al (2000) Depression, hopelessness, and desire for hastened death in terminally ill patients with cancer. JAMA. 284:2907–2911CrossRefPubMed
4.
Zurück zum Zitat Sioka C, Kyritsis AP (2009) Central and peripheral nervous system toxicity of common chemotherapeutic agents. Cancer Chemother Pharmacol 63:761–767CrossRefPubMed Sioka C, Kyritsis AP (2009) Central and peripheral nervous system toxicity of common chemotherapeutic agents. Cancer Chemother Pharmacol 63:761–767CrossRefPubMed
5.
Zurück zum Zitat Ahles TA, Saykin AJ, Furstenberg CT et al (2002) Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 20:485–493CrossRefPubMed Ahles TA, Saykin AJ, Furstenberg CT et al (2002) Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 20:485–493CrossRefPubMed
6.
Zurück zum Zitat Wieneke MH, Dienst ER (1995) Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psycho-Oncology 4:61–66CrossRef Wieneke MH, Dienst ER (1995) Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psycho-Oncology 4:61–66CrossRef
7.
Zurück zum Zitat Castellon SA, Ganz PA, Bower JE, Petersen L, Abraham L, Greendale GA (2004) Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol 26:955–969CrossRefPubMed Castellon SA, Ganz PA, Bower JE, Petersen L, Abraham L, Greendale GA (2004) Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol 26:955–969CrossRefPubMed
8.
Zurück zum Zitat Wefel JS, Lenzi R, Theriault R, Buzdar AU, Cruickshank S, Meyers CA (2004) ‘Chemobrain’ in breast carcinoma?: a prologue. Cancer. 101:466–475CrossRefPubMed Wefel JS, Lenzi R, Theriault R, Buzdar AU, Cruickshank S, Meyers CA (2004) ‘Chemobrain’ in breast carcinoma?: a prologue. Cancer. 101:466–475CrossRefPubMed
9.
Zurück zum Zitat Vardy J, Rourke S, Tannock IF (2007) Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research. J Clin Oncol 25:2455–2463CrossRefPubMed Vardy J, Rourke S, Tannock IF (2007) Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research. J Clin Oncol 25:2455–2463CrossRefPubMed
10.
Zurück zum Zitat Vardy J, Wefel JS, Ahles T, Tannock IF, Schagen SB (2008) Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol 19:623–629CrossRefPubMed Vardy J, Wefel JS, Ahles T, Tannock IF, Schagen SB (2008) Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol 19:623–629CrossRefPubMed
11.
Zurück zum Zitat McDonald BC, Conroy SK, Ahles TA, West JD, Saykin AJ (2010) Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study. Breast Cancer Res Treat 123:819–828CrossRefPubMedPubMedCentral McDonald BC, Conroy SK, Ahles TA, West JD, Saykin AJ (2010) Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study. Breast Cancer Res Treat 123:819–828CrossRefPubMedPubMedCentral
12.
13.
Zurück zum Zitat Ponto LL, Menda Y, Magnotta VA, Yamada TH, Denburg NL, Schultz SK (2015) Frontal hypometabolism in elderly breast cancer survivors determined by [(18)F] fluorodeoxyglucose (FDG) positron emission tomography (PET): a pilot study. Int J Geriatr Psychiatry 30:587–594CrossRefPubMed Ponto LL, Menda Y, Magnotta VA, Yamada TH, Denburg NL, Schultz SK (2015) Frontal hypometabolism in elderly breast cancer survivors determined by [(18)F] fluorodeoxyglucose (FDG) positron emission tomography (PET): a pilot study. Int J Geriatr Psychiatry 30:587–594CrossRefPubMed
14.
Zurück zum Zitat Selamat MH, Loh SY, Mackenzie L, Vardy J (2014) Chemobrain experienced by breast cancer survivors: a meta-ethnography study investigating research and care implications. PLoS One 9(9):e108002CrossRefPubMedPubMedCentral Selamat MH, Loh SY, Mackenzie L, Vardy J (2014) Chemobrain experienced by breast cancer survivors: a meta-ethnography study investigating research and care implications. PLoS One 9(9):e108002CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Biglia N, Bounous VE, Malabaila A et al (2012) Objective and self-reported cognitive dysfunction in breast cancer women treated with chemotherapy: a prospective study. Eur J Cancer Care (Engl) 21:485–492CrossRef Biglia N, Bounous VE, Malabaila A et al (2012) Objective and self-reported cognitive dysfunction in breast cancer women treated with chemotherapy: a prospective study. Eur J Cancer Care (Engl) 21:485–492CrossRef
16.
Zurück zum Zitat Hutchinson AD, Hosking JR, Kichenadasse G, Mattiske JK, Wilson C (2012) Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review. Cancer Treat Rev 38:926–934CrossRefPubMed Hutchinson AD, Hosking JR, Kichenadasse G, Mattiske JK, Wilson C (2012) Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review. Cancer Treat Rev 38:926–934CrossRefPubMed
17.
Zurück zum Zitat Craig CD, Monk BJ, Farley JH (2014) Chase DM (2014). Cognitive impairment in gynecologic cancers: a systematic review of current approaches to diagnosis and treatment. Support Care Cancer 22:279–287CrossRefPubMed Craig CD, Monk BJ, Farley JH (2014) Chase DM (2014). Cognitive impairment in gynecologic cancers: a systematic review of current approaches to diagnosis and treatment. Support Care Cancer 22:279–287CrossRefPubMed
18.
Zurück zum Zitat Correa DD, Zhou Q, Thaler HT, Maziarz M, Hurley K, Hensley ML (2010) Cognitive functions in long-term survivors of ovarian cancer. Gynecol Oncol 119:366–369CrossRefPubMed Correa DD, Zhou Q, Thaler HT, Maziarz M, Hurley K, Hensley ML (2010) Cognitive functions in long-term survivors of ovarian cancer. Gynecol Oncol 119:366–369CrossRefPubMed
19.
Zurück zum Zitat Meyers CA, Byrne KS, Komaki R (1995) Cognitive deficits in patients with small cell lung cancer before and after chemotherapy. Lung Cancer 12:231–235CrossRefPubMed Meyers CA, Byrne KS, Komaki R (1995) Cognitive deficits in patients with small cell lung cancer before and after chemotherapy. Lung Cancer 12:231–235CrossRefPubMed
20.
Zurück zum Zitat Komaki R, Meyers CA, Shin DM et al (1995) Evaluation of cognitive function in patients with limited small cell lung cancer prior to and shortly following prophylactic cranial irradiation. Int J Radiat Oncol Biol Phys 33:179–182CrossRefPubMed Komaki R, Meyers CA, Shin DM et al (1995) Evaluation of cognitive function in patients with limited small cell lung cancer prior to and shortly following prophylactic cranial irradiation. Int J Radiat Oncol Biol Phys 33:179–182CrossRefPubMed
21.
Zurück zum Zitat Grosshans DR, Meyers CA, Allen PK, Davenport SD, Komaki R (2008) Neurocognitive function in patients with small cell lung cancer: effect of prophylactic cranial irradiation. Cancer. 112:589–595CrossRefPubMed Grosshans DR, Meyers CA, Allen PK, Davenport SD, Komaki R (2008) Neurocognitive function in patients with small cell lung cancer: effect of prophylactic cranial irradiation. Cancer. 112:589–595CrossRefPubMed
22.
Zurück zum Zitat Schagen SB, Boogerd W, Muller MJ et al (2008) Cognitive complaints and cognitive impairment following BEP chemotherapy in patients with testicular cancer. Acta Oncol 47:63–70CrossRefPubMed Schagen SB, Boogerd W, Muller MJ et al (2008) Cognitive complaints and cognitive impairment following BEP chemotherapy in patients with testicular cancer. Acta Oncol 47:63–70CrossRefPubMed
23.
Zurück zum Zitat Pedersen AD, Rossen P, Mehlsen MY, Pedersen CG, Zachariae R, von der Maase H (2009) Long-term cognitive function following chemotherapy in patients with testicular cancer. J Int Neuropsychol Soc 15:296–301CrossRefPubMed Pedersen AD, Rossen P, Mehlsen MY, Pedersen CG, Zachariae R, von der Maase H (2009) Long-term cognitive function following chemotherapy in patients with testicular cancer. J Int Neuropsychol Soc 15:296–301CrossRefPubMed
24.
Zurück zum Zitat Skaali T, Fossa SD, Andersson S et al (2011) A prospective study of neuropsychological functioning in testicular cancer patients. Ann Oncol 22:1062–1070CrossRefPubMed Skaali T, Fossa SD, Andersson S et al (2011) A prospective study of neuropsychological functioning in testicular cancer patients. Ann Oncol 22:1062–1070CrossRefPubMed
25.
Zurück zum Zitat Wefel JS, Vidrine DJ, Veramonti TL et al (2011) Cognitive impairment in men with testicular cancer prior to adjuvant therapy. Cancer. 117:190–196CrossRefPubMed Wefel JS, Vidrine DJ, Veramonti TL et al (2011) Cognitive impairment in men with testicular cancer prior to adjuvant therapy. Cancer. 117:190–196CrossRefPubMed
26.
Zurück zum Zitat van Dam FS, Schagen SB, Muller MJ et al (1998) Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 90:210–218CrossRefPubMed van Dam FS, Schagen SB, Muller MJ et al (1998) Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 90:210–218CrossRefPubMed
27.
Zurück zum Zitat Brezden CB, Phillips KA et al (2000) Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 18:2695–2701CrossRefPubMed Brezden CB, Phillips KA et al (2000) Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 18:2695–2701CrossRefPubMed
28.
Zurück zum Zitat Tchen N, Juffs HG, Downie FP et al (2003) Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol 21:4175–4183CrossRefPubMed Tchen N, Juffs HG, Downie FP et al (2003) Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol 21:4175–4183CrossRefPubMed
29.
Zurück zum Zitat Shilling V, Jenkins V, Fallowfield L, Howell T (2003) The effects of hormone therapy on cognition in breast cancer. J Steroid Biochem Mol Biol 86:405–412CrossRefPubMed Shilling V, Jenkins V, Fallowfield L, Howell T (2003) The effects of hormone therapy on cognition in breast cancer. J Steroid Biochem Mol Biol 86:405–412CrossRefPubMed
30.
Zurück zum Zitat Shilling V, Jenkins V, Morris R, Deutsch G, Bloomfield D (2005) The effects of adjuvant chemotherapy on cognition in women with breast cancer—preliminary results of an observational longitudinal study. Breast. 14:142–150CrossRefPubMed Shilling V, Jenkins V, Morris R, Deutsch G, Bloomfield D (2005) The effects of adjuvant chemotherapy on cognition in women with breast cancer—preliminary results of an observational longitudinal study. Breast. 14:142–150CrossRefPubMed
31.
Zurück zum Zitat Scherwath A, Mehnert A, Schleimer B et al (2006) Neuropsychological function in high-risk breast cancer survivors after stem-cell supported high-dose therapy versus standard-dose chemotherapy: evaluation of long-term treatment effects. Ann Oncol 17:415–423CrossRefPubMed Scherwath A, Mehnert A, Schleimer B et al (2006) Neuropsychological function in high-risk breast cancer survivors after stem-cell supported high-dose therapy versus standard-dose chemotherapy: evaluation of long-term treatment effects. Ann Oncol 17:415–423CrossRefPubMed
32.
Zurück zum Zitat Jansen CE, Dodd MJ, Miaskowski CA, Dowling GA, Kramer J (2008) Preliminary results of a longitudinal study of changes in cognitive function in breast cancer patients undergoing chemotherapy with doxorubicin and cyclophosphamide. Psychooncology. 17:1189–1195CrossRefPubMed Jansen CE, Dodd MJ, Miaskowski CA, Dowling GA, Kramer J (2008) Preliminary results of a longitudinal study of changes in cognitive function in breast cancer patients undergoing chemotherapy with doxorubicin and cyclophosphamide. Psychooncology. 17:1189–1195CrossRefPubMed
33.
Zurück zum Zitat Jansen CE, Cooper BA, Dodd MJ, Miaskowski CA (2010) A prospective longitudinal study of chemotherapy-induced cognitive changes in breast cancer patients. Support Care Cancer 19:1647–1656CrossRefPubMed Jansen CE, Cooper BA, Dodd MJ, Miaskowski CA (2010) A prospective longitudinal study of chemotherapy-induced cognitive changes in breast cancer patients. Support Care Cancer 19:1647–1656CrossRefPubMed
34.
Zurück zum Zitat Ahles TA, Saykin AJ, McDonald BC et al (2010) Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol 28:4434–4440CrossRefPubMedPubMedCentral Ahles TA, Saykin AJ, McDonald BC et al (2010) Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol 28:4434–4440CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Ahles TA, Saykin AJ, McDonald BC et al (2008) Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res Treat 110:143–152CrossRefPubMed Ahles TA, Saykin AJ, McDonald BC et al (2008) Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res Treat 110:143–152CrossRefPubMed
36.
Zurück zum Zitat Vearncombe KJ, Rolfe M, Wright M, Pachana NA, Andrew B, Beadle GJ (2009) Predictors of cognitive decline after chemotherapy in breast cancer patients. J Int Neuropsychol Soc 15:951–962CrossRefPubMed Vearncombe KJ, Rolfe M, Wright M, Pachana NA, Andrew B, Beadle GJ (2009) Predictors of cognitive decline after chemotherapy in breast cancer patients. J Int Neuropsychol Soc 15:951–962CrossRefPubMed
37.
Zurück zum Zitat Schilder CM, Eggens PC, Seynaeve C et al (2009) Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study. Acta Oncol 48:76–85CrossRefPubMed Schilder CM, Eggens PC, Seynaeve C et al (2009) Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study. Acta Oncol 48:76–85CrossRefPubMed
38.
Zurück zum Zitat Quesnel C, Savard J, Ivers H (2009) Cognitive impairments associated with breast cancer treatments: results from a longitudinal study. Breast Cancer Res Treat 116:113–123CrossRefPubMed Quesnel C, Savard J, Ivers H (2009) Cognitive impairments associated with breast cancer treatments: results from a longitudinal study. Breast Cancer Res Treat 116:113–123CrossRefPubMed
39.
Zurück zum Zitat Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA (2004) The cognitive sequeale of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 100:2292–2299CrossRefPubMed Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA (2004) The cognitive sequeale of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 100:2292–2299CrossRefPubMed
40.
Zurück zum Zitat Wefel JS, Saleeba AK, Buzdar AU, Meyers CA (2010) Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer 116:3348–3356CrossRefPubMed Wefel JS, Saleeba AK, Buzdar AU, Meyers CA (2010) Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer 116:3348–3356CrossRefPubMed
41.
Zurück zum Zitat Schagen SB, Muller MJ, Boogerd W et al (2002) Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Ann Oncol 13:1387–1397CrossRefPubMed Schagen SB, Muller MJ, Boogerd W et al (2002) Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Ann Oncol 13:1387–1397CrossRefPubMed
42.
Zurück zum Zitat Donovan KA, Small BJ, Andrykowski MA, Schmitt FA, Munster P, Jacobsen PB (2005) Cognitive functioning after adjuvant chemotherapy and/or radiotherapy for early-stage breast carcinoma. Cancer. 104:2499–2507CrossRefPubMed Donovan KA, Small BJ, Andrykowski MA, Schmitt FA, Munster P, Jacobsen PB (2005) Cognitive functioning after adjuvant chemotherapy and/or radiotherapy for early-stage breast carcinoma. Cancer. 104:2499–2507CrossRefPubMed
43.
Zurück zum Zitat Hermelink K, Untch M, Lux MP et al (2007) Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer. 109:1905–1913CrossRefPubMed Hermelink K, Untch M, Lux MP et al (2007) Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer. 109:1905–1913CrossRefPubMed
44.
Zurück zum Zitat Debess J, Riis JO, Engebjerg MC, Ewertz M (2010) Cognitive function after adjuvant treatment for early breast cancer: a population-based longitudinal study. Breast Cancer Res Treat 121:91–100CrossRefPubMed Debess J, Riis JO, Engebjerg MC, Ewertz M (2010) Cognitive function after adjuvant treatment for early breast cancer: a population-based longitudinal study. Breast Cancer Res Treat 121:91–100CrossRefPubMed
45.
Zurück zum Zitat Cheung YT, Ng T, Shwe M et al (2015) Association of proinflammatory cytokines and chemotherapy-associated cognitive impairment in breast cancer patients: a multi-centered, prospective, cohort study. Ann Oncol 26:1446–1451CrossRefPubMedPubMedCentral Cheung YT, Ng T, Shwe M et al (2015) Association of proinflammatory cytokines and chemotherapy-associated cognitive impairment in breast cancer patients: a multi-centered, prospective, cohort study. Ann Oncol 26:1446–1451CrossRefPubMedPubMedCentral
47.
Zurück zum Zitat Verstappen CC, Heimans JJ, Hoekman K, Postma TJ (2003) Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs. 63:1549–1563CrossRefPubMed Verstappen CC, Heimans JJ, Hoekman K, Postma TJ (2003) Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs. 63:1549–1563CrossRefPubMed
48.
Zurück zum Zitat Silverman DH, Dy CJ, Castellon SA et al (2007) Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy. Breast Cancer Res Treat 103:303–311CrossRefPubMed Silverman DH, Dy CJ, Castellon SA et al (2007) Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy. Breast Cancer Res Treat 103:303–311CrossRefPubMed
49.
Zurück zum Zitat Jacobsen PB, Garland LL, Booth-Jones M et al (2004) Relationship of hemoglobin levels to fatigue and cognitive functioning among cancer patients receiving chemotherapy. J Pain Symptom Manag 28:7–18CrossRef Jacobsen PB, Garland LL, Booth-Jones M et al (2004) Relationship of hemoglobin levels to fatigue and cognitive functioning among cancer patients receiving chemotherapy. J Pain Symptom Manag 28:7–18CrossRef
50.
Zurück zum Zitat Porta C, Imarisio I, De Amici M (2005) Pro-neoangiogenic cytokines (VEGF and bFGF) and anemia in solid tumor patients. Oncol Rep 13:689–695PubMed Porta C, Imarisio I, De Amici M (2005) Pro-neoangiogenic cytokines (VEGF and bFGF) and anemia in solid tumor patients. Oncol Rep 13:689–695PubMed
51.
Zurück zum Zitat Aapro M, Osterborg A, Gascón P, Ludwig H, Beguin Y (2012) Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron. Ann Oncol 23:1954–1962CrossRefPubMed Aapro M, Osterborg A, Gascón P, Ludwig H, Beguin Y (2012) Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron. Ann Oncol 23:1954–1962CrossRefPubMed
52.
Zurück zum Zitat Tsavaris N, Kosmas C et al (2002) Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer 87(1):21–27CrossRefPubMedPubMedCentral Tsavaris N, Kosmas C et al (2002) Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer 87(1):21–27CrossRefPubMedPubMedCentral
53.
Zurück zum Zitat Lechner K, Obermeier HL (2012) Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases. Medicine (Baltimore) 91:195–205CrossRef Lechner K, Obermeier HL (2012) Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases. Medicine (Baltimore) 91:195–205CrossRef
54.
Zurück zum Zitat Kelley KW, Bluthe RM et al (2003) Cytokine-induced sickness behavior. Brain Behav Immun 17(Suppl 1):S112–S118CrossRefPubMed Kelley KW, Bluthe RM et al (2003) Cytokine-induced sickness behavior. Brain Behav Immun 17(Suppl 1):S112–S118CrossRefPubMed
55.
Zurück zum Zitat Nadin SB, Vargas-Roig LM, Drago G, Ibarra J, Ciocca DR (2006) DNA damage and repair in peripheral blood lymphocytes from healthy individuals and cancer patients: a pilot study on the implications in the clinical response to chemotherapy. Cancer Lett 239:84–97CrossRefPubMed Nadin SB, Vargas-Roig LM, Drago G, Ibarra J, Ciocca DR (2006) DNA damage and repair in peripheral blood lymphocytes from healthy individuals and cancer patients: a pilot study on the implications in the clinical response to chemotherapy. Cancer Lett 239:84–97CrossRefPubMed
56.
Zurück zum Zitat Bender CM, Paraska KK et al (2001) Cognitive function and reproductive hormones in adjuvant therapy for breast cancer: a critical review. J Pain Symptom Manag 21(5):407–424CrossRef Bender CM, Paraska KK et al (2001) Cognitive function and reproductive hormones in adjuvant therapy for breast cancer: a critical review. J Pain Symptom Manag 21(5):407–424CrossRef
57.
Zurück zum Zitat Jenkins VA, Bloomfield DJ, Shilling VM, Edginton TL (2005) Does neoadjuvant hormone therapy for early prostate cancer affect cognition? Results from a pilot study. BJU Int 96:48–53CrossRefPubMed Jenkins VA, Bloomfield DJ, Shilling VM, Edginton TL (2005) Does neoadjuvant hormone therapy for early prostate cancer affect cognition? Results from a pilot study. BJU Int 96:48–53CrossRefPubMed
58.
Zurück zum Zitat Unfer TC, Conterato GM, da Silva JC, Duarte MM, Emanuelli T (2006) Influence of hormone replacement therapy on blood antioxidant enzymes in menopausal women. Clin Chim Acta 369:73–77CrossRefPubMed Unfer TC, Conterato GM, da Silva JC, Duarte MM, Emanuelli T (2006) Influence of hormone replacement therapy on blood antioxidant enzymes in menopausal women. Clin Chim Acta 369:73–77CrossRefPubMed
59.
60.
Zurück zum Zitat Ahles TA, Saykin AJ, Noll WW et al (2003) The relationship of APOE genotype to neuropsychological performances in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology. 12:612–619CrossRefPubMed Ahles TA, Saykin AJ, Noll WW et al (2003) The relationship of APOE genotype to neuropsychological performances in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology. 12:612–619CrossRefPubMed
61.
Zurück zum Zitat Miller S, Lo C, Gagliese L et al (2011) Patterns of depression in cancer patients: an indirect test of gender-specific vulnerabilities to depression. Soc Psychiatry Psychiatr Epidemiol 46:767–774CrossRefPubMed Miller S, Lo C, Gagliese L et al (2011) Patterns of depression in cancer patients: an indirect test of gender-specific vulnerabilities to depression. Soc Psychiatry Psychiatr Epidemiol 46:767–774CrossRefPubMed
62.
Zurück zum Zitat Angelino AF, Treisman GJ (2001) Major depression and demoralization in cancer patients: diagnostic and treatment considerations. Support Care Cancer 9:344–349CrossRefPubMed Angelino AF, Treisman GJ (2001) Major depression and demoralization in cancer patients: diagnostic and treatment considerations. Support Care Cancer 9:344–349CrossRefPubMed
63.
Zurück zum Zitat Ciaramella A1, Poli P (2001) Assessment of depression among cancer patients: the role of pain, cancer type and treatment. Psychooncology. 10:156–165CrossRefPubMed Ciaramella A1, Poli P (2001) Assessment of depression among cancer patients: the role of pain, cancer type and treatment. Psychooncology. 10:156–165CrossRefPubMed
64.
Zurück zum Zitat McDaniel JS, Musselman DL, Porter MR, Reed DA, Nemeroff CB (1995) Depression in patients with cancer. Diagnosis, biology, and treatment. Arch Gen Psychiatry 52:89–99CrossRefPubMed McDaniel JS, Musselman DL, Porter MR, Reed DA, Nemeroff CB (1995) Depression in patients with cancer. Diagnosis, biology, and treatment. Arch Gen Psychiatry 52:89–99CrossRefPubMed
65.
Zurück zum Zitat Endicott J (1984) Measurement of depression in patients with cancer. Cancer 53(10 Suppl):2243–2249CrossRefPubMed Endicott J (1984) Measurement of depression in patients with cancer. Cancer 53(10 Suppl):2243–2249CrossRefPubMed
66.
Zurück zum Zitat Bukberg J, Penman D, Holland JC (1984) Depression in hospitalized cancer patients. Psychosom Med 46:199–212CrossRefPubMed Bukberg J, Penman D, Holland JC (1984) Depression in hospitalized cancer patients. Psychosom Med 46:199–212CrossRefPubMed
67.
Zurück zum Zitat Gil F, Costa G, Hilker I, Benito L (2012) First anxiety, afterwards depression: psychological distress in cancer patients at diagnosis and after medical treatment. Stress Health 28:362–367CrossRefPubMed Gil F, Costa G, Hilker I, Benito L (2012) First anxiety, afterwards depression: psychological distress in cancer patients at diagnosis and after medical treatment. Stress Health 28:362–367CrossRefPubMed
68.
Zurück zum Zitat Stewart A, Collins B, Mackenzie J, Tomiak E, Verma S, Bielajew C (2008) The cognitive effects of adjuvant chemotherapy in early stage breast cancer: a prospective study. Psychooncology. 17:122–130CrossRefPubMed Stewart A, Collins B, Mackenzie J, Tomiak E, Verma S, Bielajew C (2008) The cognitive effects of adjuvant chemotherapy in early stage breast cancer: a prospective study. Psychooncology. 17:122–130CrossRefPubMed
69.
Zurück zum Zitat Ando-Tanabe N, Iwamitsu Y, Kuranami M et al (2014) Cognitive function in women with breast cancer receiving adjuvant chemotherapy and healthy controls. Breast Cancer 21:453–462CrossRefPubMed Ando-Tanabe N, Iwamitsu Y, Kuranami M et al (2014) Cognitive function in women with breast cancer receiving adjuvant chemotherapy and healthy controls. Breast Cancer 21:453–462CrossRefPubMed
70.
Zurück zum Zitat Montazeri A, Milroy R, Hole D, McEwen J, Gillis CR (1998) Anxiety and depression in patients with lung cancer before and after diagnosis: findings from a population in Glasgow, Scotland. J Epidemiol Community Health 52:203–204CrossRefPubMedPubMedCentral Montazeri A, Milroy R, Hole D, McEwen J, Gillis CR (1998) Anxiety and depression in patients with lung cancer before and after diagnosis: findings from a population in Glasgow, Scotland. J Epidemiol Community Health 52:203–204CrossRefPubMedPubMedCentral
71.
Zurück zum Zitat Hopwood P, Stephens RJ (2000) Depression in patients with lung cancer: prevalence and risk factors derived from quality-of-life data. J Clin Oncol 8:893–903CrossRef Hopwood P, Stephens RJ (2000) Depression in patients with lung cancer: prevalence and risk factors derived from quality-of-life data. J Clin Oncol 8:893–903CrossRef
72.
Zurück zum Zitat Shilling V, Jenkins V (2007) Self-reported cognitive problems in women receiving adjuvant therapy for breast cancer. Eur J Oncol Nurs 11:6–15CrossRefPubMed Shilling V, Jenkins V (2007) Self-reported cognitive problems in women receiving adjuvant therapy for breast cancer. Eur J Oncol Nurs 11:6–15CrossRefPubMed
73.
Zurück zum Zitat Boykoff N, Moieni M, Subramanian SK (2009) Confronting chemobrain: an in-depth look at survivors’ reports of impact on work, social networks, and health care response. J Cancer Surviv 3:223–232CrossRefPubMedPubMedCentral Boykoff N, Moieni M, Subramanian SK (2009) Confronting chemobrain: an in-depth look at survivors’ reports of impact on work, social networks, and health care response. J Cancer Surviv 3:223–232CrossRefPubMedPubMedCentral
74.
Zurück zum Zitat Munir F, Burrows J, Yarker J, Kalawsky K, Bains M (2010) Women’s perceptions of chemotherapy-induced cognitive side effects on work ability: a focus group study. J Clin Nurs 19:1362–1370CrossRefPubMed Munir F, Burrows J, Yarker J, Kalawsky K, Bains M (2010) Women’s perceptions of chemotherapy-induced cognitive side effects on work ability: a focus group study. J Clin Nurs 19:1362–1370CrossRefPubMed
75.
Zurück zum Zitat Massie MJ (2004) Prevalence of depression in patients with cancer. J Natl Cancer Inst Monogr 2004:57–71CrossRef Massie MJ (2004) Prevalence of depression in patients with cancer. J Natl Cancer Inst Monogr 2004:57–71CrossRef
76.
Zurück zum Zitat Hotopf M, Chidgey J, Addington-Hall J, Ly KL (2002) Depression in advanced disease: a systematic review. Part 1. Prevalence and case finding. Palliat Med 16:81–97CrossRefPubMed Hotopf M, Chidgey J, Addington-Hall J, Ly KL (2002) Depression in advanced disease: a systematic review. Part 1. Prevalence and case finding. Palliat Med 16:81–97CrossRefPubMed
77.
Zurück zum Zitat Poppelreuter M, Weis J, Kulz AK, Tucha O, Lange KW, Bartsch HH (2004) Cognitive dysfunction and subjective complaints of cancer patients. A cross-sectional study in a cancer rehabilitation centre. Eur J Cancer 40:43–49CrossRefPubMed Poppelreuter M, Weis J, Kulz AK, Tucha O, Lange KW, Bartsch HH (2004) Cognitive dysfunction and subjective complaints of cancer patients. A cross-sectional study in a cancer rehabilitation centre. Eur J Cancer 40:43–49CrossRefPubMed
78.
Zurück zum Zitat Croyle RT, Rowland JH (2003) Mood disorders and cancer: a National Cancer Institute perspective. Biol Psychiatry 54:191–194CrossRefPubMed Croyle RT, Rowland JH (2003) Mood disorders and cancer: a National Cancer Institute perspective. Biol Psychiatry 54:191–194CrossRefPubMed
79.
Zurück zum Zitat Ganz PA (2012) Doctor, will the treatment you are recommending cause chemobrain? J Clin Oncol 30:229–231CrossRefPubMed Ganz PA (2012) Doctor, will the treatment you are recommending cause chemobrain? J Clin Oncol 30:229–231CrossRefPubMed
80.
Zurück zum Zitat Wefel JS, Kesler SR, Noll KR, Schagen SB (2015) Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. CA Cancer J Clin 65:123–138CrossRefPubMed Wefel JS, Kesler SR, Noll KR, Schagen SB (2015) Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. CA Cancer J Clin 65:123–138CrossRefPubMed
81.
Zurück zum Zitat Von Ah D, Carpenter JS, Saykin A et al (2012) Advanced cognitive training for breast cancer survivors: a randomized controlled trial. Breast Cancer Res Treat 135(3):799–809CrossRef Von Ah D, Carpenter JS, Saykin A et al (2012) Advanced cognitive training for breast cancer survivors: a randomized controlled trial. Breast Cancer Res Treat 135(3):799–809CrossRef
82.
Zurück zum Zitat Kesler S, Hadi Hosseini SM, Heckler C et al (2013) Cognitive training for improving executive function in chemotherapy-treated breast cancer survivors. Clin Breast Cancer 13:299–306CrossRefPubMedPubMedCentral Kesler S, Hadi Hosseini SM, Heckler C et al (2013) Cognitive training for improving executive function in chemotherapy-treated breast cancer survivors. Clin Breast Cancer 13:299–306CrossRefPubMedPubMedCentral
83.
Zurück zum Zitat Player L, Mackenzie L, Willis K, Loh SY (2014) Women’s experiences of cognitive changes or ‘chemobrain’ following treatment for breast cancer: a role for occupational therapy? Aust Occup Ther J 61:230–240CrossRefPubMed Player L, Mackenzie L, Willis K, Loh SY (2014) Women’s experiences of cognitive changes or ‘chemobrain’ following treatment for breast cancer: a role for occupational therapy? Aust Occup Ther J 61:230–240CrossRefPubMed
84.
Zurück zum Zitat Hotting K, Roder B (2013) Beneficial effects of physical exercise on neuroplasticity and cognition. Neurosci Biobehav Rev 37:2243–2257CrossRefPubMed Hotting K, Roder B (2013) Beneficial effects of physical exercise on neuroplasticity and cognition. Neurosci Biobehav Rev 37:2243–2257CrossRefPubMed
85.
Zurück zum Zitat Fitzpatrick TR, Edgar L, Holcroft C (2012) Assessing the relationship between physical fitness activities, cognitive health, and quality of life among older cancer survivors. J Psychosoc Oncol 30:556–572CrossRefPubMed Fitzpatrick TR, Edgar L, Holcroft C (2012) Assessing the relationship between physical fitness activities, cognitive health, and quality of life among older cancer survivors. J Psychosoc Oncol 30:556–572CrossRefPubMed
86.
Zurück zum Zitat Morone G, Iosa M, Fusco A et al (2014) Effects of a multidisciplinary educational rehabilitative intervention in breast cancer survivors: the role of body image on quality of life outcomes. Sci World J 2014:451935CrossRef Morone G, Iosa M, Fusco A et al (2014) Effects of a multidisciplinary educational rehabilitative intervention in breast cancer survivors: the role of body image on quality of life outcomes. Sci World J 2014:451935CrossRef
87.
Zurück zum Zitat Morone G, Pisotta I, Pichiorri F et al (2015) Proof of principle of a brain-computer interface approach to support poststroke arm rehabilitation in hospitalized patients: design, acceptability, and usability. Arch Phys Med Rehabil 96(3 Suppl):S71–S78CrossRefPubMed Morone G, Pisotta I, Pichiorri F et al (2015) Proof of principle of a brain-computer interface approach to support poststroke arm rehabilitation in hospitalized patients: design, acceptability, and usability. Arch Phys Med Rehabil 96(3 Suppl):S71–S78CrossRefPubMed
88.
Zurück zum Zitat Alvarez J, Meyer FL, Granoff DL, Lundy A (2013) The effect of EEG biofeedback on reducing postcancer cognitive impairment. Integr Cancer Ther 12:475–487CrossRefPubMed Alvarez J, Meyer FL, Granoff DL, Lundy A (2013) The effect of EEG biofeedback on reducing postcancer cognitive impairment. Integr Cancer Ther 12:475–487CrossRefPubMed
89.
Zurück zum Zitat Borghgraef C, Libert Y, Etienne AM, Delvaux N, Reynaert C, Razavi D (2014) Treatment of cognitive impairments in oncology: a review of longitudinal controlled studies. Bull Cancer 101:866–875CrossRefPubMed Borghgraef C, Libert Y, Etienne AM, Delvaux N, Reynaert C, Razavi D (2014) Treatment of cognitive impairments in oncology: a review of longitudinal controlled studies. Bull Cancer 101:866–875CrossRefPubMed
90.
Zurück zum Zitat Heflin LH, Meyerowitz BE et al (2005) Cancer as a risk factor for long-term cognitive deficits and dementia. J Natl Cancer Inst 97:854–856CrossRefPubMed Heflin LH, Meyerowitz BE et al (2005) Cancer as a risk factor for long-term cognitive deficits and dementia. J Natl Cancer Inst 97:854–856CrossRefPubMed
91.
Zurück zum Zitat Kurita K, Meyerowitz BE et al (2011) Long-term cognitive impairment in older adult twins discordant for gynecologic cancer treatment. J Gerontol A Biol Sci Med Sci 66:1343–1349CrossRefPubMed Kurita K, Meyerowitz BE et al (2011) Long-term cognitive impairment in older adult twins discordant for gynecologic cancer treatment. J Gerontol A Biol Sci Med Sci 66:1343–1349CrossRefPubMed
Metadaten
Titel
Neuropsychological disorders in non-central nervous system cancer: a review of objective cognitive impairment, depression, and related rehabilitation options
verfasst von
Fulvia Di Iulio
Luca Cravello
Jacob Shofany
Stefano Paolucci
Carlo Caltagirone
Giovanni Morone
Publikationsdatum
02.05.2019
Verlag
Springer International Publishing
Erschienen in
Neurological Sciences / Ausgabe 9/2019
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-019-03898-0

Weitere Artikel der Ausgabe 9/2019

Neurological Sciences 9/2019 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.